Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)-Reference-Cited by-同舟云学术

Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)

Published:2024-07 Issue: Volume:47 Page:100790
ISSN:2405-6308
Container-title:Clinical and Translational Radiation Oncology
language:en
Short-container-title:Clinical and Translational Radiation Oncology

Author:

Maier Sebastian H.^ORCID,Schönecker Stephan^ORCID,Anagnostatou Vasiliki^ORCID,Garny Sylvia,Nitschmann Alexander^ORCID,Fleischmann Daniel F.,Büttner Marcel,Kaul David,Imhoff Detlef^ORCID,Fokas Emmanouil,Seidel Clemens^ORCID,Hau Peter,Kölbl Oliver,Popp Ilinca,Grosu Anca-Ligia,Haussmann Jan,Budach Wilfried,Celik Eren,Kahl Klaus-Henning^ORCID,Hoffmann Elgin^ORCID,Tabatabai Ghazaleh,Paulsen Frank,Holzgreve Adrien^ORCID,Albert Nathalie L.,Mansmann Ulrich,Corradini Stefanie,Belka Claus,Niyazi Maximilian,Bodensohn Raphael^ORCID

Funder

German Cancer Aid

Publisher

Elsevier BV

Reference32 articles.

1. Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12);Bodensohn;Clin Transl Radiat Oncol,2024

2. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03;Tsien;Int J Radiat Oncol Biol Phys,2009

3. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma;Tsien;Clin Cancer Res,2012

4. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide;Badiyan;Int J Radiat Oncol Biol Phys,2014

5. Initial results of a phase 2 trial of (18)F-DOPA PET-guided dose-escalated radiation therapy for glioblastoma;Laack;Int J Radiat Oncol Biol Phys,2021